Home › Non-Hodgkin Lymphoma › Ohio › Cleveland
Pag-aaral pangklinika para sa Non-Hodgkin Lymphoma sa Cleveland, OH
Isang pag-aaral para sa Non-Hodgkin Lymphoma ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Cleveland. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Nagre-recruitPhase 1/2
- University Hospitals Seidman Cancer Center, Cleveland
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Nagre-recruitPhase 1
- Cleveland Clinic, Cleveland
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Nagre-recruitPhase 1
- Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, Cleveland
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Nagre-recruitPhase 1
- Clinical Trial Site, Cleveland
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Nagre-recruitPhase 1/2
- Cleveland Clinic, Cleveland
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Nagre-recruitPhase 3
- Cleveland Clinical Taussig Cancer Center, Cleveland
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Nagre-recruitObservasyonal na pag-aaral
- University Hospitals Case Medical Center, Cleveland
- Cleveland Clinic, Cleveland
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
Nagre-recruitPhase 1
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Nagre-recruitPhase 1/2
- Cleveland Clinic, Cleveland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, Mayfield Heights · 12 mi ang layo
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Nagre-recruitPhase 1
- University Hospitals Cleveland Medical Center, Cleveland
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Nagre-recruitPhase 1/2
- University Hospitals Cleveland, Cleveland
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma
Nagre-recruitPhase 1
- University Hospitals Seidman Cancer Center, Cleveland
- Taussig Cancer Institute | Cleveland Clinic, Cleveland
Pag-aaral para sa Non-Hodgkin Lymphoma sa ibang lungsod
- New York City, NY31 pag-aaral
- Houston, TX31 pag-aaral
- Boston, MA26 pag-aaral
- Nashville, TN21 pag-aaral
- Philadelphia, PA20 pag-aaral
- Baldwin Park, CA19 pag-aaral
- Washington, DC18 pag-aaral
- Chicago, IL18 pag-aaral
- Atlanta, GA18 pag-aaral
- Milwaukee, WI18 pag-aaral
- Columbus, OH18 pag-aaral
- Dallas, TX17 pag-aaral
Iba pang pag-aaral sa Cleveland
- Non-Small Cell Lung Cancer43 pag-aaral
- Kanser (lahat ng uri)36 pag-aaral
- Kanser sa Suso35 pag-aaral
- Kanser sa Prostate34 pag-aaral
- Pagkabigo ng Puso33 pag-aaral
- Kanser sa Ovary30 pag-aaral
- Metastatic Cancer30 pag-aaral
- Kanser sa Baga26 pag-aaral
- Colorectal Cancer24 pag-aaral
- Sakit sa Puso at Ugat ng Dugo22 pag-aaral
- Kanser ng Endometrium20 pag-aaral
- Acute Myeloid Leukemia20 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.